CRISPR THERAPEUTICS AG Operating Lease, Liability, Noncurrent
CRISPR THERAPEUTICS AG (CRSP) had Operating Lease, Liability, Noncurrent of $178.90 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-03
- 2026-06-30: Operating Lease, Liability, Noncurrent $178.90M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $183.56M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $188.17M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $192.77M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $178.90M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $183.56M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $188.17M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $192.77M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $197.43M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $201.85M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $206.41M 10-K · filed 2026-02-12 |
| 2024-09-30 | $210.66M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $214.85M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $218.94M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $223.01M 10-K · filed 2025-02-11 |
| 2023-09-30 | $226.59M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $230.34M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $224.55M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $228.18M 10-K · filed 2024-02-21 |
| 2022-09-30 | $230.90M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $234.16M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $227.90M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $212.87M 10-K · filed 2023-02-21 |
| 2021-09-30 | $192.73M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $175.33M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $49.41M 10-Q · filed 2021-04-27 |
| 2020-12-31 | $50.07M 10-K · filed 2022-02-15 |
| 2020-09-30 | $38.57M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $40.32M 10-Q · filed 2020-07-27 |
| 2020-03-31 | $42.39M 10-Q · filed 2020-04-28 |
| 2019-12-31 | $44.05M 10-K · filed 2021-02-16 |
| 2019-09-30 | $36.83M 10-Q · filed 2019-10-28 |
| 2019-06-30 | $37.20M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $31.73M 10-Q · filed 2019-04-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |